Compare Abeona Therapeutics Inc (ABEO) vs Williams Companies Inc (WMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Williams Companies Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Williams Companies Inc trades at $75.12 (market cap $91.82B). The key difference: Williams Companies Inc is far larger — about 246× Abeona Therapeutics Inc's market cap, and Williams Companies Inc pays a 2.8% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WMB | |
|---|---|---|
Market Cap | $373.32M | $91.82B |
Sector | Health | Energy |
52-Week High | $7.23 | $79.40 |
52-Week Low | $4.17 | $56.51 |
Enterprise Value | $228.22M | $121.21B |
Dividend Yield | — | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Williams Companies (WMB) trades at $75.08, up 2.65% on the day, approaching its 52-week high of $80.08. The stock shows strong profitability with a 23.4% net income margin and 21.95% ROE, though valuation ratios like P/E of 31.94 appear elevated. Recent news highlights a potential $5.5 billion acquisition of Momentum Midstream to expand natural gas infrastructure, while technical indicators signal a bearish trend despite neutral oscillators.
WMB presents a mixed outlook: robust cash flow growth and a 79% analyst buy rating support upside to the $86.55 consensus target, but high debt levels and recent earnings misses pose risks. The stock's current price near resistance at $75 suggests near-term consolidation, with long-term growth hinging on successful integration of acquisitions and stable energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
